OCA
DTIL icon

Octagon Capital Advisors’s Precision BioSciences DTIL Stock Holding History

Octagon Capital Advisors’s Portfolio DTIL Stock Details DTIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.3M Buy
2,236,732
+318,737
+17% +$1.47M 1.36% 21
2025
Q4 		$7.98M Buy
+1,917,995
New +$10.9M 0.97% 24

Other funds holding DTIL

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Octagon Capital Advisors's DTIL Position: Q1 2026 in Review

Octagon Capital Advisors increased its Precision BioSciences (DTIL) stake by 17% in Q1 2026, buying an estimated $1.47M and bringing the position to 2,236,732 shares worth $12.3M. The position accounts for 1.36% of the portfolio, ranked #21.

Octagon Capital Advisors first reported a position in DTIL in Q4 2025 and has held it in 2 quarters since. 78 funds tracked by Wall St. Rank hold DTIL as of Q1 2026.

  • Octagon Capital Advisors held 2,236,732 shares of Precision BioSciences worth $12.3M as of Q1 2026.
  • Octagon Capital Advisors bought 318,737 Precision BioSciences shares in Q1 2026, an estimated $1.47M.
  • Precision BioSciences made up 1.36% of Octagon Capital Advisors's portfolio in Q1 2026, its #21 holding.
  • Octagon Capital Advisors first reported a position in Precision BioSciences in Q4 2025 and has held it in 2 quarters since.
  • 78 funds tracked by Wall St. Rank held Precision BioSciences as of Q1 2026.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.